Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Context: In Colorado children, the prevalence of diabetic ketoacidosis (DKA) at diagnosis of type 1 diabetes has been increasing over time.

Objective: To evaluate the prevalence of and factors involved in DKA at type 1 diabetes diagnosis among participants followed in monitoring research studies before diagnosis compared to patients from the community.

Methods: We studied patients < 18 years diagnosed with type 1 diabetes between 2005 and 2021 at the Barbara Davis Center for Diabetes and compared the prevalence of and factors associated with DKA at diagnosis among participants in preclinical monitoring studies vs those diagnosed in the community.

Results: Of 5049 subjects, 164 were active study participants, 42 inactive study participants, and 4843 were community patients. Active study participants, compared to community patients, had lower HbA1c (7.3% vs 11.9%; P < .001) and less frequently experienced DKA (4.9% vs 48.5%; P < .001), including severe DKA (1.2% vs 16.2%; P < .001). Inactive study participants had intermediate levels for both prevalence and severity of DKA. DKA prevalence increased in community patients, from 44.0% to 55%, with less evidence for a temporal trend in study participants. DKA prevalence was highest in children < 2 years (13% in active study participants vs 83% in community patients). In community patients, younger age (P = .0038), public insurance (P < .0001), rural residence (P < .0076), higher HbA1c (P < .0001), and ethnicity minority status (P < .0001) were associated with DKA at diagnosis.

Conclusion: While DKA prevalence increases in community patients over time, it stayed < 5% in active research participants, who have a 10 times lower prevalence of DKA at diagnosis, including among minorities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651691PMC
http://dx.doi.org/10.1210/clinem/dgae158DOI Listing

Publication Analysis

Top Keywords

study participants
24
community patients
24
diagnosis participants
12
dka diagnosis
12
type diabetes
12
active study
12
dka prevalence
12
dka
11
participants
10
lower prevalence
8

Similar Publications

Due to the increase in the number of infliximab products, the need for global harmonization of the bioactivity of this monoclonal antibody was recognized by the World Health Organization (WHO). In response, the National Institute for Biological Standards and Control (NIBSC) developed the first international standard (IS) for infliximab, which targets tumour necrosis factor (TNF). Each ampoule is assigned values of 500 IU of TNF neutralizing activity and 500 IU of binding activity.

View Article and Find Full Text PDF